Imunon, Inc. is a clinical stage oncology drug company. The company is headquartered in Lawrenceville, New Jersey and currently employs 25 full-time employees. The firm is focused on advancing a portfolio of treatments that harness the body’s natural mechanisms across an array of human diseases, constituting a differentiating approach from conventional therapies. The firm is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas, is developed for the gene-based delivery of cytokines and other therapeutic proteins in the treatment of solid tumors. The second modality, PlaCCine, is developed for the gene delivery of viral antigens that can elicit a strong immunological response. The Company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer that has completed Phase 2 development. IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site.
Dr. Stacy Lindborg 2021 'den beri şirketle birlikte olan Imunon Inc 'in President 'ıdır.
IMNN hissesinin fiyat performansı nasıl?
IMNN 'in mevcut fiyatı $2.87 'dir, son işlem günde 0% azalmış etti.
Imunon Inc için ana iş temaları veya sektörler nelerdir?
Imunon Inc Biotechnology endüstrisine ait ve sektör Health Care 'dir
Imunon Inc 'in piyasa değerlemesi nedir?
Imunon Inc 'in mevcut piyasa değerlemesi $8.8M 'dir
Imunon Inc al, sat, yoksa beklemeli mi?
Wall Street analistlerine göre, 6 analist Imunon Inc için analist derecelendirmeleri gerçekleştirdi, bunlar 2 güçlü al, 6 al, 2 tut, 0 sat ve 2 güçlü sat içermektedir